Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease (PD ... may be more prone to treatment-emergent adverse ...

Creation of a permanent lesion in the subthalamic nucleus (STN) might provide an alternative approach to deep brain stimulation (DBS) in the treatment of Parkinson disease when the latter ...

have begun using the latest technology — adaptive deep brain stimulation — in his treatment for Parkinson’s disease, a neurodegenerative disorder. “Mr. Schena has had Parkinson’s disease ...

Parkinson's disease, named after him, is the second most common neurodegenerative disease after Alzheimer's. To date, there is no causal treatment for Parkinson's syndrome—only symptoms can be ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are ...

Co., Ltd. for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson's disease (PD), the second most common neurodegenerative ...

April 11, 2025 – Two incurable diseases loom over our aging populace: Parkinson's and ... professionals make other treatment decisions and can be useful in broader disease research.

Additionally, SUNRISE-PD is to our knowledge one of only a handful of trials to evaluate a potential treatment for Parkinson’s disease while allowing patients to participate remotely through a ...

The Bottom Line The earlier someone gets diagnosed for Parkinson’s disease the better. “The timing of diagnosis is important because the sooner someone starts treatment, the more mobile ...

In February, Johnson underwent a new procedure that uses MRI imaging and ultrasound beams to target and destroy small areas of cells in the brain responsible for causing Parkinson’s symptoms.